Skip to content

Transdiagnostic Cognitive Biomarkers

Transdiagnostic Cognitive Biomarkers

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04864080
Enrollment
48
Registered
2021-04-28
Start date
2022-04-11
Completion date
2027-03-01
Last updated
2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Pain

Brief summary

The overall objective of this study is to determine the feasibility of identifying transdiagnostic biomarkers of cognitive function mediated by neuromodulation of the dorsolateral prefrontal cortex that are translatable across disease groups in order to more accurately phenotype clusters of cognitive dysfunction. Completing behavioral paradigms with electrophysiology and TMS is a challenging frontier. This study focuses on the feasibility of such an endeavor for those with chronic pain or depression as well as healthy controls.

Detailed description

This study aims to test the feasibility of procedures aimed at discovering transdiagnostic biomarkers for cognitive impairment in chronic pain and depression. Fifteen healthy control participants and 15 participants from each disease group (chronic pain, depression) will be recruited. Using a task-based fmri, TMS will be targeted for priming of the Left DLPFC. EEG will be used during our behavioral paradigm to compare changes in DLPFC function before and after primed TMS.

Interventions

BEHAVIORALComputer game/task

N-back, COGED, PacMan game, Bandit task, Websurf task.

BEHAVIORALHealth surveys online

Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Feasibility study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Arm 1, healthy controls: Inclusion Criteria: * Have access to the online study platform.

Exclusion criteria

* under 18, non-English speaking Arm 2: pain and depression: Inclusion Criteria: * Pain or depression

Design outcomes

Primary

MeasureTime frameDescription
Feasibility for all aspects of the study1-7 daysFeasibility; the overall objective of this study is to determine the feasibility of identifying transdiagnostic biomarkers of cognitive function mediated by neuromodulation of the dorsolateral prefrontal cortex that are translatable across disease groups in order to more accurately phenotype clusters of cognitive dysfunction. Completing behavioral paradigms with electrophysiology and TMS is a challenging frontier. This study focuses on the feasibility of such an endeavor for those with chronic pain or depression as well as healthy controls.

Secondary

MeasureTime frameDescription
Acceptability1-7 daysSum total of acceptability rating scale of study procedures.

Countries

United States

Contacts

CONTACTDavid Darrow
hdlab@umn.edu(612) 624-6666
CONTACTMATTHEW D Maple
maple036@umn.edu612-946-1424

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026